Replies to post #140569 on Biotech Values

[oc631]

We also saw viral relapse and breakthrough in some supposedly easier to treat GT2/3 arm. So, there might be something else going there.

That did come as a surprise considering this happened in GT2/GT3 patients.

If you consider the fact SVR rates like this have rarely been seen with interferon-based therapy, and relapse/breakthrough are common occurrences under existing SOC, I feel there's much to be excited about.